Marshall Wace, LLP Coherus Bio Sciences, Inc. Transaction History

Marshall Wace, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.58 - $2.51 $424,645 - $674,595	268,763 Added 177.33%	420,326 $727,000
Q1 2024 May 15, 2024	BUY	$2.02 - $3.14 $69,453 - $107,962	34,383 Added 29.34%	151,563 $362,000
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $3.49 Million - $8.45 Million	-2,195,026 Reduced 94.93%	117,180 $390,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $107,768 - $157,041	28,815 Added 1.26%	2,312,206 $8.65 Million
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $6.48 Million - $14.2 Million	1,710,463 Added 298.55%	2,283,391 $9.75 Million
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $3.37 Million - $6.03 Million	572,928 New	572,928 $3.92 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $218,928 - $423,506	30,534 New	30,534 $294,000
Q2 2021 Aug 13, 2021	SELL	$12.95 - $15.41 $448,199 - $533,340	-34,610 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $499,076 - $740,307	34,610 New	34,610 $505,000
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $152,225 - $218,252	-9,339 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$13.1 - $22.1 $122,340 - $206,391	9,339 New	9,339 $207,000
Q4 2018 Feb 14, 2019	SELL	$8.65 - $16.28 $2.05 Million - $3.86 Million	-237,182 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $3.05 Million - $4.27 Million	210,824 Added 799.85%	237,182 $3.91 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $270,169 - $459,947	26,358 New	26,358 $369,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.